Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.76 |
| ▸ | RAB9A | P51151 | 13/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | HTT | P42858 | 4/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.76 |
| ▸ | JAK2 | O60674 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 6/20 | 0.67 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | TNF | P01375 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.53 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30748820 | 1.00 | NPC1 (0.76) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL2493403 | 0.87 | NPC1 (1.00) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL30748835 | 0.86 | MAPT (0.57) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL30749057 | 0.84 | MAPT (0.55) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL30749024 | 0.82 | NPC1 (0.56) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL17203946 | 0.82 | NPC1 (0.73) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL15428401 | 0.81 | NPC1 (1.00) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL30749027 | 0.81 | ALDH1A1 (0.58) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL15428400 | 0.81 | NPC1 (1.00) | NPC1RAB9AMAPTHTTKMT2A | |
| SCHEMBL30749090 | 0.80 | NPC1 (0.74) | NPC1RAB9AMAPTHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8865708-B2 | Methods and compositions for inhibition of the transitional endoplasmic reticulum ATPase | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2014-10-21 | — | — | US | disclosed |
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288082-A1 | METHODS AND COMPOSITIONS FOR INHIBITION OF THE TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE | VCP, PSMG3, PSMB3 | NPC1 516/4885RAB9A 2208/4885MAPT 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.